These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results

Core Viewpoint - Regeneron Pharmaceuticals reported strong fourth-quarter earnings, exceeding market expectations in both earnings per share and sales figures [1][3]. Financial Performance - The company posted adjusted earnings of $11.44 per share, a decrease of 5% year-over-year, but above the consensus estimate of $10.71 [1]. - Sales reached $3.88 billion, reflecting a 3% year-over-year increase, surpassing the consensus of $3.79 billion [1]. Future Projections - For fiscal 2026, Regeneron anticipates a GAAP gross margin of 79%–80% and an adjusted gross margin of 83%–84% [2]. - The company forecasts adjusted R&D expenses between $5.9 billion and $6.1 billion, with non-GAAP SG&A expenditures projected to be between $2.5 billion and $2.65 billion [2]. Market Reaction - Following the earnings announcement, Regeneron shares increased by 2.1%, trading at $756.63 [3]. - Analysts have adjusted their price targets for Regeneron Pharmaceuticals in light of the earnings report [3].